Redx Ready To Get Back To The Clinic After Tough Year
Executive Summary
CEO Lisa Anson has brought "a sense of urgency, focus and realism" to Redx since she took over five months ago, says its chairman, and the firm has high hopes for its investigational porcupine inhibitors.
You may also be interested in...
Redx Raises Funds And Remains Independent
Redx's takeover talks with a consortium led by controversial biotech veteran Sam Waksal, who was jailed for five years over his role in the ImClone stock scandal in 2003, have been terminated but the UK biotech has received a financial lifeline from Redmile and Sofinnova.
Buzz Grows Around Biotech At Former AstraZeneca Campus
Chris Doherty, managing director of the UK's Alderley Park, tells Scrip that the departure of the drug giant from its global R&D headquarters has acted as a catalyst to create a vibrant biotech cluster that is attractive to local, national and international companies.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.